Quince Therapeutics, Inc.
QNCX
$34.04
$1.635.03%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 14.53M | 15.05M | 15.70M | 16.05M | 17.40M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.61M | 50.43M | 44.30M | 41.48M | 40.43M |
| Operating Income | -48.61M | -50.43M | -44.30M | -41.48M | -40.43M |
| Income Before Tax | -35.21M | -80.77M | -56.90M | -48.90M | -60.61M |
| Income Tax Expenses | -2.17M | 3.21M | 75.00K | 134.00K | 103.00K |
| Earnings from Continuing Operations | -33.04 | -83.98 | -56.98 | -49.03 | -60.71 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.04M | -83.98M | -56.98M | -49.03M | -60.71M |
| EBIT | -48.61M | -50.43M | -44.30M | -41.48M | -40.43M |
| EBITDA | -48.46M | -50.29M | -44.18M | -41.32M | -40.25M |
| EPS Basic | -188.39 | -328.71 | -243.91 | -219.53 | -279.46 |
| Normalized Basic EPS | -108.51 | -174.39 | -129.92 | -127.06 | -110.03 |
| EPS Diluted | -202.73 | -328.71 | -243.91 | -219.53 | -279.46 |
| Normalized Diluted EPS | -108.74 | -174.39 | -129.92 | -127.06 | -110.03 |
| Average Basic Shares Outstanding | 1.24M | 1.00M | 941.80K | 887.80K | 869.90K |
| Average Diluted Shares Outstanding | 1.24M | 1.00M | 941.80K | 887.80K | 869.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |